Navigation Links
Cardiologists initiate STILETTO study to investigate treatment options for women with chest pain
Date:2/24/2009

CHICAGO Women who experience chest pain are sent to a cardiologist to go through a standard battery of tests, and often times test results show no evidence of coronary artery disease which is the most common cause of chest pain. This is a less common occurrence in men, and these women are sent home with little more than reassurance but often times return to their physicians complaining of similar symptoms and are more likely to develop future cardiac events.

To better determine the cause of difficult to diagnose chest pain among women, physicians at Northwestern Memorial's Bluhm Cardiovascular Institute are initiating a research study designed to identify the prevalence of a condition called Syndrome X. This disease process affects the endothelial function of blood vessels, a condition where the layers of the cells are not functioning properly and may be undetectable by standard testing such as exercise stress test and cardiac angiography. Researchers believe that endothelial dysfunction is the earliest stage of coronary artery disease. The goal of the study is to determine a more accurate diagnosis for women who present with chest pain symptoms and to determine if a more aggressive treatment regimen than the current standard of care may be adopted in the future.

In women there may be a different disease process which could be due to endothelial dysfunction, which is not something that can be detected by the current standard of care regimen. "Given that endothelial dysfunction may be an early stage of atherosclerosis, or fat deposits in the arteries, some have suggested medical treatment and lifestyle changes similar to those recommended to women with obstructive coronary artery disease," says Martha Gulati, MD, associate medical director of the Center for Women's Cardiovascular Health and assistant professor of medicine at Northwestern University's Feinberg School of Medicine.

"There are currently no other randomized trials comparing the effectiveness of such therapy in women with cardiac symptoms, normal coronary arteries but evidence of coronary endothelial dysfunction," commented Neil Stone, MD, medical director of the Center for Vascular Disease and professor of medicine at Northwestern University's Feinberg School of Medicine.

Study participants will undergo endothelial dysfunction testing, a procedure where medication is injected into the coronary arteries to directly assess endothelial response of the arteries, in order to identify women who may be likely to develop coronary artery disease and who would benefit from aggressive lifestyle and medical interventions. These interventions include dietary counseling, exercise, and medical treatment targeting improving the endothelial dysfunction.


'/>"/>

Contact: Amy Dobrozsi
adobrozs@nmh.org
312-926-5900
Northwestern Memorial Hospital
Source:Eurekalert

Related medicine news :

1. One-Third of U.S. Primary Care Physicians and Cardiologists Do Not Currently Prescribe Treatment to Meet HDL Cholesterol Targets as Recommended By National Guidelines
2. Cardiologists Warn Proposed Changes Would Close Outpatient Cardiac Cath Labs
3. Cardiologists Spot Best Treatment for a Deadly Duo
4. Distinguished Cardiologists and Scientists Honored With 2008 International Academy of Cardiology Award
5. Dallas Cardiologists Explore Next Frontier in Vascular-Disease Treatments
6. Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C.
7. SCAIs Annual Fall Fellows Course Prepares New Interventional Cardiologists to Work in the Field
8. Res-Q Gains Rights To Market Orosine - a Breakthrough, Patented, Natural Heart Supplement That Cardiologists Are Calling the Ultimate Cardio Protection Against Heart Attacks, Strokes and Heart Failure.
9. Among Cardiologists, Women Cite Discrimination
10. Video: Cardiologists Recommend Lifestyle Habits for Healthy Hearts
11. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... A new ... with severe congenital diaphragmatic hernia have better survival rates if surgery is performed ... (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs into ...
(Date:4/29/2016)... PA (PRWEB) , ... April 29, 2016 , ... ... announced that student team BioCellection won the $30,000 Perlman Grand Prize of the ... Prize, the Gloeckner Undergraduate Award, the Michelson People’s Choice Award, and the Committee ...
(Date:4/29/2016)... ... April 29, 2016 , ... World Patent Marketing ... an exercise invention which aids in proper muscle development. , "The Gym & ... Creative Director of World Patent Marketing. "Globalization has threatened the future growth of ...
(Date:4/29/2016)... ... ... the deadliest type of skin cancer. Although only about 1 percent of skin cancer cases ... 10,000 people are expected to die of melanoma this year. The risk increases with age, ... most commonly diagnosed cancers in young women. A recent breakthrough in genetic studies may give ...
(Date:4/29/2016)... New York, NY (PRWEB) , ... April 29, 2016 , ... New York City based ... surgery . This surgery is a very effective way to treat obstructive sleep apnea. Dr. ... , Orthognathic surgery is a procedure that involves one or both jaw bones. This ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 ... consumer insights on healthcare, announced today that it has ... report Cool Vendor in Life Sciences, 2016, ... 15, 2016.  The report focuses on life-science- oriented analytics, ... insight from patients and doctors, confirm medication ingestion, and ...
(Date:4/28/2016)... , April 28, 2016  ValGenesis, ... Lifecycle Management Solutions (VLMS) today announced that ... services for sufferers of chronic kidney failure ... to manage their corporate validation process. The ... a software solution to manage their validation ...
(Date:4/27/2016)... 2016   ... sur le trimestre, soutenu par une croissance de ... Croissance de +16% des ventes aux hôpitaux et ... Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventeur de ... son chiffre d,affaires pour le premier trimestre clos ...
Breaking Medicine Technology: